About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Cholangiocarcinoma Market Analysis and Forecasts, 2025-2035 | Targeted Therapies Like Pemigatinib, Infigratinib, and Ivosidenib Revolutionize Treatment for Patients with Actionable Mutations - ResearchAndMarkets.com

The "Cholangiocarcinoma Market - A Global and Regional Analysis: Focus on Type, Therapy Type, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

The global cholangiocarcinoma market is undergoing significant transformation, driven by increasing disease incidence, advancements in diagnostic techniques, and the development of novel therapeutic strategies. Cholangiocarcinoma, or bile duct cancer, is a rare but aggressive malignancy that presents late and has limited treatment options, resulting in high unmet medical needs. This has prompted major investments in R&D and a shift toward precision medicine to improve survival outcomes.

The global cholangiocarcinoma market growth is primarily supported by improved screening protocols and enhanced awareness among healthcare professionals, leading to earlier diagnosis and intervention. Progress in biomarker-based diagnostics and imaging technologies is further bolstering detection rates. As the standard of care evolves, combination therapies involving surgery, chemotherapy, targeted drugs, and immunotherapy are being adopted for better patient outcomes. Key drugs such as pemigatinib, infigratinib, and ivosidenib are making headway in transforming treatment for patients with actionable mutations.

Therapy pipelines are expanding rapidly, with ongoing clinical trials evaluating the efficacy of new targeted and immunotherapeutic agents. These include immune checkpoint inhibitors, FGFR2 and IDH1 inhibitors, and advanced radiation modalities. Regulatory support through orphan drug designations and fast-track approvals is catalyzing market access and incentivizing innovation in the cholangiocarcinoma landscape.

The cholangiocarcinoma market will continue evolving with a focus on patient-specific therapeutics, biomarker-driven drug development, and integrated care approaches to address the complex nature of this rare cancer. Advances in genomic profiling are enabling the identification of actionable mutations, allowing for more tailored treatment strategies. Meanwhile, multidisciplinary care models are being increasingly adopted, combining oncology, hepatology, radiology, and palliative services to optimize clinical outcomes and improve quality of life. These shifts are redefining the treatment paradigm for cholangiocarcinoma and are expected to drive sustained growth and innovation in the coming years.

However, several significant challenges continue to hinder broader progress. Nearly 65% of cholangiocarcinoma cases are diagnosed at an advanced stage. The global five-year survival rate remains below 10%. Enrollment in clinical trials is impacted by a small eligible population, and treatment costs often exceed $100,000 annually in developed markets. Access disparities persist, with fewer than 1 oncologist per 100,000 people in many low- and middle-income countries. Despite these hurdles, the market outlook remains optimistic, with breakthroughs in clinical research and evolving therapeutic approaches paving the way for future growth.

The competitive landscape of the cholangiocarcinoma market is characterized by strategic collaborations, especially among oncology-focused biopharmaceutical firms and academic institutions, are accelerating the pace of discovery and commercialization. The influx of precision oncology approaches and growing focus on rare cancers is likely to strengthen the global market footprint. Integration of AI in diagnostics, along with digital health tools for patient monitoring, is expected to further refine care delivery and enhance outcomes.

Looking ahead, the global cholangiocarcinoma market is projected to sustain robust growth underpinned by innovative therapies, enhanced diagnostic accuracy, and increasing healthcare investments across both developed and developing regions. Continued emphasis on combination therapies and personalized treatment regimens will be central to improving survival and quality of life for cholangiocarcinoma patients worldwide.

Companies Featured

  • Incyte
  • BridgeBio Pharma
  • TAIHO ONCOLOGY, INC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Servier Pharmaceuticals LLC
  • AstraZeneca
  • Bayer AG
  • Bristol Myers Squibb

Market Segmentation:

Type

  • Intrahepatic cholangiocarcinoma
  • Hilar cholangiocarcinoma
  • Distal cholangiocarcinoma

Therapy Type

  • Surgical Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Palliative Care
  • Combination Therapy

Region

  • North America
  • Europe
  • Asia-Pacific

Key Topics Covered:

1. Global Cholangiocarcinoma Market: Industry Analysis

1.1 Market Overview and Ecosystem

1.2 Epidemiological Analysis

1.3 Key Market Trends

1.3.1 Impact Analysis

1.4 Patent Analysis

1.4.1 Patent Filing Trend (by Country)

1.4.2 Patent Filing Trend (by Year)

1.5 Regulatory Landscape

1.6 Ongoing Clinical Trials

1.7 Market Dynamics

1.7.1 Overview

1.7.2 Market Drivers

1.7.3 Market Restraints

1.7.4 Market Opportunities

2. Global Cholangiocarcinoma Market, by Type, $Million, 2023-2035

2.1 Intrahepatic cholangiocarcinoma

2.2 Hilar cholangiocarcinoma

2.3 Distal cholangiocarcinoma

3. Global Cholangiocarcinoma Market, by Therapy Type, $Million, 2023-2035

3.1 Surgical Therapy

3.2 Chemotherapy

3.3 Targeted Therapy

3.4 Immunotherapy

3.5 Radiation Therapy

3.6 Palliative Care

3.7 Combination Therapy

4. Global Cholangiocarcinoma Market, by Region, $Million, 2023-2035

4.1 North America

4.1.1 Market Dynamics

4.1.2 Market Sizing and Forecast

4.1.3 North America Cholangiocarcinoma Market, by Country

4.1.3.1 U.S.

4.2 Europe

4.2.1 Market Dynamics

4.2.2 Market Sizing and Forecast

4.2.3 Europe Cholangiocarcinoma Market, by Country

4.2.3.1 U.K.

4.2.3.2 France

4.2.3.3 Germany

4.2.3.4 Italy

4.2.3.5 Spain

4.3 Asia-Pacific

4.3.1 Market Dynamics

4.3.2 Market Sizing and Forecast

4.3.3 Asia-Pacific Cholangiocarcinoma Market, by Country

4.3.3.1 Japan

5. Global Cholangiocarcinoma Market, Competitive Landscape and Company Profiles

5.1 Competitive Landscape

5.1.1 Mergers and Acquisitions

5.1.2 Partnership, Alliances and Business Expansion

5.1.3 New Offerings

5.1.4 Regulatory Activities

5.1.5 Funding Activities

5.2 Company Profiles

5.2.1 Overview

5.2.2 Top Products / Product Portfolio

5.2.3 Top Competitors

5.2.4 Target Customers/End-Users

5.2.5 Key Personnel

5.2.6 Analyst View

For more information about this report visit https://www.researchandmarkets.com/r/t8hfhu

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.